Medical Disclaimer

Anthivera is an editorial and informational website. It is not a medical provider, a pharmacy, or a substitute for professional medical care.

The content on Anthivera — including articles, peptide explainers, provider comparisons, guides, newsletters, and any other material — is provided for general informational and educational purposes only. It is not medical advice, and it is not intended to diagnose, treat, cure, or prevent any disease or health condition.

No doctor-patient relationship#

Reading Anthivera, contacting us, subscribing to our email list, or using any tool on this site does not create a doctor-patient, provider-patient, or any other professional or fiduciary relationship between you and Anthivera or anyone associated with it.

Always consult a qualified professional#

Decisions about peptides, hormones, supplements, medications, or any other health intervention should be made only in consultation with a licensed physician or other qualified healthcare provider who knows your individual medical history. Never disregard, avoid, or delay seeking professional medical advice because of something you read on Anthivera. If you think you may have a medical emergency, call your doctor or emergency services immediately.

On peptides specifically — and the 2026 regulatory situation#

Many peptides discussed on this site are not approved by the U.S. Food and Drug Administration (FDA) for the uses described, and some are not approved for any use. The regulatory landscape for compounded peptides changed materially in 2026 and is still evolving:

• In late 2023, the FDA placed 19 peptides on Category 2 ("do not compound"), restricting compounding-pharmacy access.
• Effective April 23, 2026, approximately 12 of those peptides were removed from Category 2. Removal from Category 2 is not the same as Category 1 status, and Category 1 is not the same as FDA approval. Formal rulemaking is still pending.
• A Pharmacy Compounding Advisory Committee (PCAC) meeting is scheduled for July 23–24, 2026 to evaluate a subset of peptides for formal inclusion on the 503A Bulks List.
• CJC-1295 specifically remains classified as a developmental drug with adverse nonclinical findings — it is not part of the group moving toward reinstatement.
• Peptides sold as "research chemicals / not for human consumption" are a separate, unregulated gray market. Selling them for human use is illegal regardless of any reclassification.

Information on Anthivera reflects our understanding as of each page's updated date and may not reflect the current regulatory status. We make no representation that any peptide is safe, effective, legal, or appropriate for you. Verify current regulatory status with a licensed provider and a licensed pharmacy.

No endorsement or recommendation#

Where Anthivera compares or describes providers, products, or services, we are providing editorial information for comparison, not a recommendation that any particular option is right for you or your medical situation. We do not recommend specific treatments for specific conditions.

No guarantee of accuracy#

We work to keep content accurate and current, but medical and regulatory information evolves quickly. We make no warranty, express or implied, regarding the completeness, accuracy, reliability, or timeliness of any content. Any reliance you place on this information is strictly at your own risk.

Individual results vary#

Any outcomes, experiences, or results referenced on this site are not promises or predictions of what you will experience.

Acknowledgment#

By using Anthivera, you acknowledge that you have read, understood, and agree to this Medical Disclaimer. Questions: hello@anthivera.com.